New Data Shows Part D Savings Took Hit Due to Price Increases on RA Drugs

A new study published in JAMA Network Open suggests patients took a big hit on savings for RA drugs under Part D due to annual price increases, Helio Rheumatology reports.

“Our study showed that despite the recent closure of the Medicare Part D coverage gap, or ‘donut hole,’ yearly increases in drug list prices have already eroded much of the anticipated savings for RA patients on specialty therapy,” Vanderbilt University School of Medicine’s Alexandra Erath told Healio Rheumatology. “On average, in 2010, before the Part D donut hole was closed, the estimated annual out-of-pocket spending for a patient chronically using these drugs was $5,858.”

To read the full Healio Rheumatology report, click here.